I really wouldn't put Pfizer i

2021-08-02

I really wouldn't put Pfizer in the same group as Apple, Amazon, and the like. What makes those stocks really strong are the lack of scaling costs (meaning they can scale up easily), and strong network effects leading to high barriers of entry (no one can easily compete with them). Pfizer doesn't have any of these advantages, it's recent performance is largely driven by the covid pandemic - which is temporary by nature.

Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":805518351,"tweetId":"805518351","gmtCreate":1627891472473,"gmtModify":1703497286242,"author":{"id":3582105537582633,"idStr":"3582105537582633","authorId":3582105537582633,"authorIdStr":"3582105537582633","name":"jaster","avatar":"https://static.tigerbbs.com/b92224d225d7e1526b126af370834bb3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>I really wouldn't put Pfizer in the same group as Apple, Amazon, and the like. What makes those stocks really strong&nbsp;are the lack of scaling costs (meaning they can scale up easily), and strong network effects leading to high barriers of entry (no one can easily compete with them). Pfizer doesn't have any of these advantages, it's recent performance is largely driven by the covid pandemic - which is temporary by nature.</p></body></html>","htmlText":"<html><head></head><body><p>I really wouldn't put Pfizer in the same group as Apple, Amazon, and the like. What makes those stocks really strong&nbsp;are the lack of scaling costs (meaning they can scale up easily), and strong network effects leading to high barriers of entry (no one can easily compete with them). Pfizer doesn't have any of these advantages, it's recent performance is largely driven by the covid pandemic - which is temporary by nature.</p></body></html>","text":"I really wouldn't put Pfizer in the same group as Apple, Amazon, and the like. What makes those stocks really strong are the lack of scaling costs (meaning they can scale up easily), and strong network effects leading to high barriers of entry (no one can easily compete with them). Pfizer doesn't have any of these advantages, it's recent performance is largely driven by the covid pandemic - which is temporary by nature.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/805518351","repostId":2156169749,"repostType":4,"repost":{"id":"2156169749","kind":"highlight","pubTimestamp":1627864728,"share":"https://www.laohu8.com/m/news/2156169749?lang=&edition=full","pubTime":"2021-08-02 08:38","market":"us","language":"en","title":"Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.","url":"https://stock-news.laohu8.com/highlight/detail?id=2156169749","media":"Motley Fool","summary":"There's both rhyme and reason for checking out these four stocks.","content":"<p>What's worse than the fear of missing out? I'd put the fear of having already missed out high on the list. There's nothing you can do once an opportunity is gone.</p>\n<p>Some investors might be feeling as if they've already missed out on the FAANG stocks. After all, four of them --&nbsp; <b>Apple</b> (NASDAQ:AAPL), <b>Alphabet</b> (NASDAQ:GOOG) (NASDAQ:GOOGL) (whose Google unit is the \"G\" in FAANG), <b>Amazon.com</b> (NASDAQ:AMZN), and&nbsp;<b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b> (NASDAQ:FB) -- rank among the top 10 biggest companies in the world. Only&nbsp;<b>Netflix</b> (NASDAQ:NFLX) lags behind, but the streaming company still has a market cap of close to $230 billion.</p>\n<p>If you're concerned that you've missed out on a great opportunity with the FAANG stocks, don't worry. Consider buying these PfANG stocks instead.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5160b68a97ec192124c08475ad420b61\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Introducing the PfANG stocks</h2>\n<p>Aside from the fact that they're all now huge, the FAANG stocks have something else in common: They're all tech stocks. While technology remains a hot area for investors, the healthcare sector also offers tremendous growth prospects. Each of the PfANG stocks ranks as a leader in healthcare, albeit in very different ways.</p>\n<p><b>Pfizer</b> (NYSE:PFE) contributes the \"Pf\" in PfANG. The company is by far the best known of the group. Pfizer, of course, markets a blockbuster COVID-19 vaccine along with its partner, <b>BioNTech</b>. The company also has a product lineup that's loaded with other successful drugs and vaccines.</p>\n<p><b>Align Technology </b>(NASDAQ:ALGN) pioneered the clear dental aligner market. The company's Invisalign clear aligners have been used to straighten the teeth of nearly 11 million patients so far. Align also markets intraoral scanners used to create 3D images of teeth.</p>\n<p><b>Nano-X Imaging</b> (NASDAQ:NNOX) expects to disrupt the medical imaging market with its digital X-ray devices. The company recently filed for U.S. Food and Drug Administration (FDA) clearance of the first version of its multisource digital system.</p>\n<p><b>Guardant Health</b> (NASDAQ:GH) is a leader in developing liquid biopsy tests for cancer. The company's first products on the market help match patients with the best cancer therapy and enable drugmakers to develop new therapies.</p>\n<h2>What sets these stocks apart</h2>\n<p>A catchy name that sounds just like FAANG doesn't make these four stocks great picks, of course. However, there are two specific things that set these stocks apart:</p>\n<ol>\n <li>They all target a massive potential market.</li>\n <li>They all have a head start in that market.</li>\n</ol>\n<p>Pfizer has been around a long time and is by far the biggest of the PfANG stocks. The company still has multiple growth opportunities, though. One of the most significant of these is in messenger RNA (mRNA) therapies and vaccines.</p>\n<p>The company continues to work closely with BioNTech on its mRNA COVID-19 vaccine program and an mRNA flu vaccine. Pfizer plans to move forward with mRNA development on its own as well.</p>\n<p>CEO Albert Bourla stated in the company's Q2 conference call last week that Pfizer's strategy is to \"advance and unlock the full potential of mRNA.\" This strategy includes expanding its COVID-19 vaccine franchise and developing mRNA candidates targeting other infectious diseases, rare diseases, and cancer.</p>\n<p>Align Technology has generated impressive growth in recent years. The company, though, still has only captured 11% of the addressable market for clear aligners.</p>\n<p>Nano-X doesn't plan to compete for market share in the $21 billion medical imaging market; it fully intends to expand that market. The company's mobile devices cost only a fraction of current X-ray systems. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a>-thirds of the world population have no meaningful access to medical imaging. Nano-X's opportunity is wide open.</p>\n<p>Guardant Health targets a $70 billion-plus potential market in cancer therapy selection, recurrence monitoring, and early screening. There are other companies going after this market as well. However, Guardant stands as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the leaders and already has strong adoption for its initial liquid biopsy products.</p>\n<h2>Still some bite left in the FAANG stocks, too</h2>\n<p>I think that the PfANG stocks could deliver market-beating returns over the long term. But you don't really need to worry about having already missed out on the FAANG stocks.</p>\n<p>Augmented reality and virtual reality present big growth opportunities for Facebook and Apple. Artificial intelligence should serve as a growth driver for both of these stocks as well as Alphabet. Netflix is moving into gaming. These FAANG stocks should still have some bite left in them.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Out on the FAANG Stocks? Consider Buying These PfANG Stocks Instead.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 08:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/01/missed-out-on-the-faang-stocks-consider-buying-the/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What's worse than the fear of missing out? I'd put the fear of having already missed out high on the list. There's nothing you can do once an opportunity is gone.\nSome investors might be feeling as if...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/01/missed-out-on-the-faang-stocks-consider-buying-the/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NNOX":"Nano-X Imaging Ltd.","AMZN":"亚马逊","GOOG":"谷歌","NFLX":"奈飞","GH":"Guardant Health Inc.","GOOGL":"谷歌A","PFE":"辉瑞","ALGN":"艾利科技","AAPL":"苹果"},"source_url":"https://www.fool.com/investing/2021/08/01/missed-out-on-the-faang-stocks-consider-buying-the/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156169749","content_text":"What's worse than the fear of missing out? I'd put the fear of having already missed out high on the list. There's nothing you can do once an opportunity is gone.\nSome investors might be feeling as if they've already missed out on the FAANG stocks. After all, four of them --  Apple (NASDAQ:AAPL), Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL) (whose Google unit is the \"G\" in FAANG), Amazon.com (NASDAQ:AMZN), and Facebook (NASDAQ:FB) -- rank among the top 10 biggest companies in the world. Only Netflix (NASDAQ:NFLX) lags behind, but the streaming company still has a market cap of close to $230 billion.\nIf you're concerned that you've missed out on a great opportunity with the FAANG stocks, don't worry. Consider buying these PfANG stocks instead.\nImage source: Getty Images.\nIntroducing the PfANG stocks\nAside from the fact that they're all now huge, the FAANG stocks have something else in common: They're all tech stocks. While technology remains a hot area for investors, the healthcare sector also offers tremendous growth prospects. Each of the PfANG stocks ranks as a leader in healthcare, albeit in very different ways.\nPfizer (NYSE:PFE) contributes the \"Pf\" in PfANG. The company is by far the best known of the group. Pfizer, of course, markets a blockbuster COVID-19 vaccine along with its partner, BioNTech. The company also has a product lineup that's loaded with other successful drugs and vaccines.\nAlign Technology (NASDAQ:ALGN) pioneered the clear dental aligner market. The company's Invisalign clear aligners have been used to straighten the teeth of nearly 11 million patients so far. Align also markets intraoral scanners used to create 3D images of teeth.\nNano-X Imaging (NASDAQ:NNOX) expects to disrupt the medical imaging market with its digital X-ray devices. The company recently filed for U.S. Food and Drug Administration (FDA) clearance of the first version of its multisource digital system.\nGuardant Health (NASDAQ:GH) is a leader in developing liquid biopsy tests for cancer. The company's first products on the market help match patients with the best cancer therapy and enable drugmakers to develop new therapies.\nWhat sets these stocks apart\nA catchy name that sounds just like FAANG doesn't make these four stocks great picks, of course. However, there are two specific things that set these stocks apart:\n\nThey all target a massive potential market.\nThey all have a head start in that market.\n\nPfizer has been around a long time and is by far the biggest of the PfANG stocks. The company still has multiple growth opportunities, though. One of the most significant of these is in messenger RNA (mRNA) therapies and vaccines.\nThe company continues to work closely with BioNTech on its mRNA COVID-19 vaccine program and an mRNA flu vaccine. Pfizer plans to move forward with mRNA development on its own as well.\nCEO Albert Bourla stated in the company's Q2 conference call last week that Pfizer's strategy is to \"advance and unlock the full potential of mRNA.\" This strategy includes expanding its COVID-19 vaccine franchise and developing mRNA candidates targeting other infectious diseases, rare diseases, and cancer.\nAlign Technology has generated impressive growth in recent years. The company, though, still has only captured 11% of the addressable market for clear aligners.\nNano-X doesn't plan to compete for market share in the $21 billion medical imaging market; it fully intends to expand that market. The company's mobile devices cost only a fraction of current X-ray systems. Two-thirds of the world population have no meaningful access to medical imaging. Nano-X's opportunity is wide open.\nGuardant Health targets a $70 billion-plus potential market in cancer therapy selection, recurrence monitoring, and early screening. There are other companies going after this market as well. However, Guardant stands as one of the leaders and already has strong adoption for its initial liquid biopsy products.\nStill some bite left in the FAANG stocks, too\nI think that the PfANG stocks could deliver market-beating returns over the long term. But you don't really need to worry about having already missed out on the FAANG stocks.\nAugmented reality and virtual reality present big growth opportunities for Facebook and Apple. Artificial intelligence should serve as a growth driver for both of these stocks as well as Alphabet. Netflix is moving into gaming. These FAANG stocks should still have some bite left in them.","news_type":1},"isVote":1,"tweetType":1,"viewCount":470,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AONE","AONE.U","PFE"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":351,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/805518351"}